Early immunochemotherapy improves survival and CD8 T cell responses in advanced non small cell lung cancer without added toxicity.

Among 854 patients analyzed, durvalumab was initiated at a median of 5.6 weeks after CCRT (IQR, 4.0-8.3 weeks). When not considering the timing of durvalumab, patients who received durvalumab had ...

Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is ...

Incremental dose to neurogenic niches correlated with reduced overall survival: SVZ HR 1.306/Gy and hippocampus HR 1.222/Gy, indicating independent adverse prognostic impact.

BERLIN October 17, 2025 – Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival ...

A cohort study examines whether the use of common medications is associated with worse outcomes in patients with lung cancer taking immunotherapy.

In this study, researchers reported on 10-year follow-up of a phase 3 trial comparing surgery to chemoradiation boost in resectable, advanced NSCLC.

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

Lung cancer cells are able to take advantage of a person’s immune system, specifically T cells, to protect the tumor, according to new research recently published in Cancer Immunology Research.